Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Lac-Leamy

Nov 14, 2024 7:30 AM - Nov 15, 2024 4:10 PM

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

Canada Annual Meeting

The Canada Annual Meeting offers three tracks, Regulatory, Clinical, Safety and Pharmacovigilance!

Time to Register!

DAYS

HOURS

MINUTES

SECONDS

Session 6, Track A and B: Insights into Rare Diseases: Pioneering Pathways for Patient Access and Drug Development

Session Chair(s)

Brenda  Gryfe, MSc

Brenda Gryfe, MSc

Regulatory Consultant

Flying Moose Technologies , Canada

Amber  McLeod, PhD

Amber McLeod, PhD

Immunology, Virology, and Specialty Head, Regulatory Affairs

Abbvie Corporation, Canada

Alysha  Croker, PhD

Alysha Croker, PhD

Director, Centre for Policy, Pediatrics and International Collaboration, BRDD

Health Canada, Canada

This session will discuss the challenges in rare disease drug development and provide updates on some exciting programs aimed at advancing therapeutic options for rare diseases. It will focus on Health Canada's National Strategy for Drugs for Rare Diseases, RareKids-CAN Pediatric Rare Disease Clinical Trials and Treatment Network, and the Critical Path Institute's Rare Disease Cures Accelerator - Data Analytics Program. These initiatives aim to increase accessibility and affordability of effective drugs, collect data to support better understanding of rare diseases, and provide drug development tools to address unmet needs in rare disease research.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the rare diseases space and how it has evolved in Canada over time
  • Discuss Health Canada’s current Regulatory environment for rare diseases
  • Identify opportunities to collaborate with various initiatives focused on supporting development of new drugs for rare diseases

Speaker(s)

Alysha  Croker, PhD

Increasing the Efficiency of Drug Development in Rare Diseases: Canadian Perspective

Alysha Croker, PhD

Health Canada, Canada

Director, Centre for Policy, Pediatrics and International Collaboration, BRDD

Thierry  Lacaze-Masmonteil, MD, PhD, FRCPC

Introduction to RareKids-CAN Pediatric Rare Disease Clinical Trials and Treatment Network

Thierry Lacaze-Masmonteil, MD, PhD, FRCPC

Maternal Infant Child and Youth Research Network (MICYRN), Canada

Scientific Director

Collin  Hovinga, PharmD, MS

Introduction to The Critical Path Institute and its Rare Disease Cures Accelerator -Data Analytics Program (RDCA-DAP)

Collin Hovinga, PharmD, MS

Critical Path Institute, United States

Vice President Rare, Orphan Pediatric Diseases Programs

Breanne  Stewart, BSN, RN

Speaker

Breanne Stewart, BSN, RN

Maternal Infant Child and Youth Research Network, Canada

Network Director, RareKids-CAN

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.